Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Entrada Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Entrada Therapeutics Inc’s stock price such as:

• Entrada Therapeutics Inc’s current stock price and volume
• Why Entrada Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for TRDA from analysts
• TRDA’s stock price momentum as measured by its relative strength

About Entrada Therapeutics Inc (TRDA)

Before we jump into Entrada Therapeutics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Want to learn more about Entrada Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Entrada Therapeutics Inc.

Entrada Therapeutics Inc’s Stock Price as of Market Close

As of July 08, 2024, 4:00 PM, CST, Entrada Therapeutics Inc’s stock price was $15.15.

Entrada Therapeutics Inc is up 7.22% from its previous closing price of $14.13.

During the last market session, Entrada Therapeutics Inc’s stock traded between $13.78 and $14.21. Currently, there are 33.50 million shares of Entrada Therapeutics Inc stock available for purchase.

Entrada Therapeutics Inc’s price-earnings (P/E) ratio is currently at 22.5, which is low compared to the Biotechnology & Medical Research industry median of 27.8. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Entrada Therapeutics Inc Stock Price History

Entrada Therapeutics Inc’s (TRDA) price is currently up 6.32% so far this month.

During the month of July, Entrada Therapeutics Inc’s stock price has reached a high of $15.20 and a low of $13.78.

Over the last year, Entrada Therapeutics Inc has hit prices as high as $18.44 and as low as $10.75. Year to date, Entrada Therapeutics Inc’s stock is up 12.06%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Entrada Therapeutics Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 05, 2024, there were 0 analysts who downgraded Entrada Therapeutics Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Entrada Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Entrada Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Entrada Therapeutics Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Entrada Therapeutics Inc (TRDA) by visiting AAII Stock Evaluator.

Relative Price Strength of Entrada Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 05, 2024, Entrada Therapeutics Inc has a weighted four-quarter relative price strength of -7.45%, which translates to a Momentum Score of 45 and is considered to be Average.

Want to learn more about how Entrada Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Entrada Therapeutics Inc Stock Price: Bottom Line

As of July 8, 2024, Entrada Therapeutics Inc’s stock price is $15.15, which is up 7.22% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Entrada Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.